Tolerability of acalabrutinib in patients with CLL: experience of a tertiary cancer care center

Leuk Lymphoma. 2023 May;64(5):1050-1053. doi: 10.1080/10428194.2023.2185089. Epub 2023 Mar 8.

Authors

Alicia McGhie¹, Jenessa Lee¹, Alessandra Ferrajoli², Adam J DiPippo¹

Affiliations

¹ Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

PMID: 36891585
DOI: 10.1080/10428194.2023.2185089

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Benzamides / adverse effects
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Protein Kinase Inhibitors / adverse effects
Protein-Tyrosine Kinases
Pyrazines / adverse effects

Substances

acalabrutinib
Protein-Tyrosine Kinases
Benzamides
Pyrazines
Protein Kinase Inhibitors